NCT04126876 - A Randomized Controlled Phase II Trial With Intradermal IMO-2125 in Pathological Tumor Stage (p) T3-4 cN0M0 Melanoma | Biotech Hunter

Enrollment

214

Participants

Timeline

Start Date

January 22, 2020

Primary Completion Date

November 1, 2021

Study Completion Date

November 1, 2031

Conditions

Malignant Melanoma

Interventions

DRUG

Tilsotolimod

Intradermal, single injection of 1 ml (8 mg) Tilsotolimod (IMO-2125) at the primary melanoma excision site, one week prior to sentinel node biopsy (SNB).

DRUG

Saline (0.9% sodium chloride)

Intradermal, single injection of 1 ml plain saline (0.9% sodium chloride) at the primary melanoma excision site, one week prior to sentinel node biopsy (SNB).

Trial Locations (1)

1081 HV

RECRUITING

VU Medical Centere, Amsterdam